Chapter 2 Drug therapy or coronary angioplasty for the treatment of coronary artery disease: new insights
|
|
- Stephen Hodges
- 5 years ago
- Views:
Transcription
1 D RUG THERAPY VS CORONARY ANGIOPLASTY R EFERENCES Chapter 2 Drug therapy or coronary angioplasty for the treatment of coronary artery disease: new insights Giovanni Amoroso Ad J. Van Boven Harry J.G.M. Crijns 31 Department of Cardiology, Thoraxcenter, University Hospital of Groningen, The Netherlands Am Heart J 2001; 141: S22-5
2 C HAPTER 2 ABSTRACT In the last decade percutaneous transluminal coronary angioplasty (PTCA) has become a very popular strategy for the treatment of coronary artery disease, although its efficacy in reducing ischemic events and the subsequent need for revascularization has yet to be proved. In this article we review the latest trials that compared PTCA and medical therapy. We discuss the potentially favorable effect of lipid-lowering therapy on coronary atherosclerosis and cardiac events, and comment on the results of a recent study (AVERT) that compared lipid-lowering treatment and PTCA in patients with stable coronary artery disease. Medical treatment aimed at reversing plaque growth and promoting plaque stabilization should probably be considered as the initial therapeutic option. Statin class drugs together with aggressive management of known risk factors show promise as the first step after appropriate early diagnosis. Revascularization procedures should subsequently be considered for all patients who do not respond to medical treatment or in whom the disease shows clear signs of progression. MEDICAL TREATMENT VS. CORONARY REVASCULARISATION 32 As reported in 1998 by the Working Group on Coronary Circulation of the European Society of Cardiology 1, in 1994 the ratio of coronary angioplasties (percutaneous transluminal coronary angioplasty, PTCA)/inhabitants in the Netherlands was 797/ 10 6, while in the rest of Europe it was 458/10 6. This difference reflects the revascularization-oriented approach to coronary artery disease that is common in Western Europe and the United States. The relative ease and safety, the lower costs when compared to surgical interventions, the continuing improvements in the pharmacological and technological aids that support these procedures, are widening the range of diagnoses for which PTCA is indicated. Patients previously treated with medication or aorto-coronary bypass are now successfully managed with a percutaneous coronary procedure. The question of whether revascularization is always the best option for any patient with coronary artery disease remains controversial. In 1995 the MASS study investigators 2 compared surgical, interventional (balloon angioplasty) and medical treatment for patients with a single stenosis of the left anterior descending artery, and found a lower incidence of medium-term adverse events only in the surgical group (3%); these authors reported no significant difference between PTCA (24%) and medical treatment (17%). Patients who received medication did not receive lipid-lowering therapy, and no stents were used in patients in the PTCA group, whereas surgically-treated patients received a mammary artery graft. At 3 years follow-up the incidence of death and infarction was similar in all three groups. Percutaneous revascularization has been compared to medical therapy in two large studies: the ACME study 3 and the RITA-2 trial 4. The ACME study, which involved single-vessel patients randomized either to PTCA or medical treatment, demonstrated a significant difference in the number of angina-free patients at 6 months follow-up in the PTCA arm (64% vs 46%) and an increase in exercise ischemic
3 D RUG THERAPY VS CORONARY ANGIOPLASTY threshold. In the RITA-2 trial, which enrolled also multivessel-diseased patients, PTCA, compared to medical treatment, reduced the percentage of patients with severe anginal status (CCS class greater than 2) at 3 months follow-up (-16.5%); exercise ischemic tolerance was also greater in this group. Despite the improved quality of life and better relief from angina, both these studies clearly showed a higher rate of adverse events in patients who underwent PTCA, so it is less certain whether this procedure is also effective in reducing ischemic events and the need for further revascularization. Interestingly, in these studies also, medical therapy did not include lipid-lowering treatment but only commonly used antiischemic drugs. LIPID LOWERING AND CORONARY ARTERY DISEASE In 1994 the 4S study 5 brought to our attention that long-term aggressive lipidlowering therapy alone could be effective in preventing adverse coronary events. Patients with a history of angina or myocardial infarction, and with levels of total cholesterol ranging between 210 mg/dl and 310 mg/dl, were treated with simvastatin (20-40 mg/daily). At 5 years follow-up they showed a significant reduction, in comparison to the placebo group, in cardiovascular-related (-42%) and total mortality (-30%) and in major cardiac events (-34%). How can lipid-lowering treatment be effective in patients with coronary heart disease other than by simply reducing blood cholesterol levels? All recent studies of coronary atherosclerosis suggest that we should consider this disease as a gradual and continuous process starting long before its clinical manifestation 6. Several physiopathological factors are probably involved in the favorable effects of HMGcoA reductase inhibitors on the atheromatous plaque-an effect that in turn helps prevent ischemic events. These factors include restoration of endothelial function, stabilization of vulnerable plaques, and retardation of plaque growth STATINS AND ENDOTHELIUM In former years the endothelium was barely considered a mechanical barrier between the vessel lumen and wall. Currently, endothelial cells must be viewed as gatekeepers in the process of sensing and reacting to stimuli, through the production of vasoactive mediators. Early endothelial dysfunction can be identified because of the paradoxical response, seen in diseased vessels, to the endothelium-dependent mediator acetylcholine. Clinical studies of hypercholesterolemic patients without clear anatomical lesions have shown an improvement after lipid-lowering therapy in myocardial perfusion, as assessed by means of SPECT technique 8, and in coronary flow reserve and coronary resistance, as assessed by means of PET technique 9. These results suggest that such patients have a basal impairment in endothelial function related to atherosclerosis in early stages, but also that these functional abnormalities are completely reversible with therapy. Several studies have also demonstrated that cholesterol-lowering treatment is able to attenuate and reverse endothelial dysfunction 10, 11, and also to reduce myocardial ischemia in patients
4 C HAPTER 2 with proven coronary artery disease: Andrews and colleagues 12, for example, demonstrated a significant reduction (-65%) in daily-life ischemic episodes for patients treated with lovastatin for 6 months. Reverting endothelial dysfunction should be a primary goal because the imbalance in endothelial function leads not only to impairment of vascular tone and myocardial perfusion, but also to accumulation of oxidized LDL, platelet adhesion, smooth muscle cell growth and the migration of inflammatory cells 13. These events are responsible for the formation of an atherosclerotic plaque, which in the early stages is usually characterized by a thin fibrous cap, a lipid-rich core, a large number of macrophages, and a slight depletion of smooth muscle cells. In recent years evidence has been emerging that soft plaques with an intermediate or minimal degree of lumen narrowing, rather than fibrous and calcified plaques with marked stenosis, are the main factors responsible for acute coronary syndromes. As a result of passive (lipid accumulation) and active (inflammatory process) phenomena, these lesions are prone to disruption and subsequently to thrombosis 14. STATINS AND PLAQUE STABILISATION AND GROWTH 34 Whereas surgical or percutaneous revascularization does not address the basic biology of coronary atherosclerosis and therefore may have little effect on plaque vulnerability, experimental studies have shown that lipid-lowering therapy is able to reduce cell replication and the inflammatory response, and to increase collagen content in the atheroma 15, 16, 17, 18, thus contributing to plaque stabilization. In 1995, the results of the REGRESS study 19, a large multicenter trial designed to assess the impact of aggressive lipid-lowering therapy on plaque regression, were first published. In this study symptomatic patients with normal or moderately elevated cholesterol levels were assigned to undergo PTCA, medical or surgical treatment, and were then randomized to receive pravastatin (40 mg/daily) or placebo. At 2 years follow-up the pravastatin-treated group showed a significant reduction in the angiographic parameters of plaque growth and progression. Most interestingly, although the luminal changes were modest, these patients also had fewer major cardiac events (-42%) and also showed a reduction (-32%) in transient myocardial ischemia, assessed as ST-segment depression episodes at ambulatory ECG 20. These results highlight the multiple potential roles of lipid-lowering treatment in restoring endothelial function and perfusion and in stabilizing and preventing plaque disruption. In vivo studies that used ultrasound imaging, and the histological findings in atherosclerotic arteries, have shown that cross-sectional vessel area is not constant because of arterial remodelling. Compensatory or inadequate enlargement and/or shrinkage are common in arteries at the site of atherosclerotic lesions or vascular interventions 21. Statin therapy may help reduce plaque growth, but this effect may be underestimated by coronary angiography due to late vascular remodelling. Nevertheless, in the PTCA subgroup in the REGRESS study, pravastatin treatment not only had a positive effect on clinical restenosis when compared to the placebo (7% vs 29%), but also reduced angiographic restenosis (mean stenosis diameter at follow-up 32% vs 45%) 22.
5 D RUG THERAPY VS CORONARY ANGIOPLASTY Newer and less invasive techniques are under development to improve the assessment of atherosclerosis. In a study that used electron-beam CT and considered the volume of coronary calcifications as a reliable index for the total burden of atherosclerotic plaques, Callister and colleagues 23 recently demonstrated that longterm therapy with statins can have a beneficial impact on slowing the progression of coronary atherosclerosis. STATINS AND/OR CORONARY ANGIOPLASTY The 1996 AVERT study was designed to compare the effect of lipid-lowering therapy and PTCA on the incidence and timing of ischemic events 24. In this trial, patients with stable angina, LDL-cholesterol levels ³115 mg/dl and one or two vessels suitable for revascularization were randomized to either atorvastatin (80 mg/daily) or PTCA. At 18 months follow-up the atorvastatin group, compared to PTCA/usual care group, showed a decrease in overall ischemic events (-36%) and a significant delay in time to the first ischemic event (36% risk reduction). No differences were reported in safety and quality of life, and patients who were treated with PTCA showed a small improvement in anginal class. These data suggest that aggressive lipid-lowering therapy, when compared to PTCA in stable patients with coronary artery disease, may be useful in reducing ischemic events and in preventing or delaying revascularization 25. Further studies are needed to understand and defeat atherosclerosis, but in the light of the present results, and considering that coronary artery disease is a continuous, gradual, long-term process, medical treatment aimed at reversing plaque growth and promoting plaque stabilization should probably be considered as the first therapeutic option. Statin class drugs together with aggressive management of known risk factors show promise as the first step after appropriate early diagnosis, and revascularization procedures should subsequently be considered for all patients who do not respond to medical treatment or in whom the disease shows clear signs of progression. 35
6 C HAPTER 2 36 References 1. Windecker S, Meyer BJ, Bonzel T. Interventional cardiology in Europe Working Group Coronary Circulation of the European Society of Cardiology. Eur Heart J 1998;19: Hueb WA, Bellotti G, Almeida de Oliveira S. The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomised trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. J Am Coll Cardiol 1995;26: Parisi AF, Folland ED, Hartigan P on behalf of the Veterans Affairs ACME investigators. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 1992;326: The RITA-2 trial participants. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) Trial. Lancet 1997; 350: The Scandinavian Simvastatin Survival Study Group. A randomised trial of cholesterol lowering in 4444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study Trail (4S). Lancet 1994;344: Gould KL. New concepts and paradigms in cardiovascular medicine: the non-invasive management of coronary artery disease. Am J Med 1998;104:2-17S. 7. Ganz P, Creager MA, Fang JC. Pathogenic mechanisms of atherosclerosis: effect of lipid lowering on the biology of atherosclerosis. Am J Med 1996;101:10-16S. 8. Eichstädt HW, Eskötter H, Hoffman I. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995;76:122-5A. 9. Siebelink HMJ, van Boven AJ, Blanksma PK. Cholesterol lowering in primary prevention improves coronary flow reserve and vascular resistances. Circulation 1998;98(S1):I Brown BG, Zhao XQ. Importance of endothelial function in mediating the benefits of lipid-lowering therapy. Am J Cardiol 1998;82:49-52T. 11. Treasure CB, Llein JL, Weintraub WS. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332: Andrews TC, Raby K, Barry J. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997;95: Gibbons GH. Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am J Cardiol 1997;79: Fuster V. Human lesion studies. Ann NY Acad Sci 1997;811: Bustos C, Hernandez Presa MA, Ortego M. HMG-coA reductase inhibition by atorvastatin in a rabbit model of atherosclerosis reduces neointimal inflammation. Am J Coll Cardiol 1998;32: Aikawa M, Rabkin E, Okada Y. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilisation. Circulation 1998;97: Kockx MM, De Meyer GR, Buyssens N. Cell composition, replication and apoptosis in atherosclerotic plaques after 6 months of cholesterol withdrawal. Circ Res 1998;83: Libby P, Aikawa M. New insights into plaque stabilisation by lipid lowering. Drugs 1998;56 S1: Jukema JW, Bruschke AVG, van Boven AJ on behalf of the REGRESS study group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:
7 D RUG THERAPY VS CORONARY ANGIOPLASTY 20. Van Boven AJ, Jukema JW, Zwinderman AH. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation 1996;94: Lerman A, Cannan CR, Higano SH. Coronary vascular remodelling in association with endothelial dysfunction. Am J Cardiol 1998;81: Mulder HJGH, Jukema JW, Bal ET. Pravastatin reduces both clinical and angiographic restenosis two years after percutaneous transluminal coronary angioplasty: an analysis of the PTCA stratum of the REGRESS study. J Am Coll Cardiol 1999;33(S A):79A. 23. Callister TQ, Raggi P, Cooil B. Effect of HMG-coA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998;339: McCormick LS, Black DM, Waters D. Rationale, design and baseline characteristics of a trial comparing aggressive lipid lowering with atorvastatin versus angioplasty treatments (AVERT). Am J Cardiol 1997;80: Pitt B, Waters D, Brown V. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341:
8 38 C HAPTER 2
9 R EFERENCES Aim of the thesis 39
10 A IM OF THE THESIS AIM OF THE THESIS As previously described in part I, coronary revascularisation is performed upon a substrate that has already been altered by the atherosclerotic process. However, revascularisation procedures can also be responsible for a further dysregulation both of endothelial and platelet function (chapter 1). Furthermore, medical interventions aimed at modulating endothelial and platelet function have demonstrated to be an effective aid and possibly a feasible alternative to coronary revascularisation (chapter 1 and 2). The aims of the thesis are: 1) To confirm that endothelial dysfunction and platelet activation preexist to coronary revascularisation and to assess whether they can influence the outcome of percutaneous and surgical interventions. 2) To clarify the direct effects of coronary revascularisation on endothelial and platelet function. 3) To determine how to reduce endothelium/platelet interaction, and possibly to improve the outcome of coronary revascularisation. 40 Given the primary involvement of endothelium in vasoregulation, in part II are described the vasomotoric response of normal and atherosclerotic coronary arteries during cardiac catheterisation (chapter 3), the endothelial release of vasoactive substances induced by percutaneous coronary intervention (chapter 4), and the long-term effect of stent deployment on coronary vasomotion, with its clinical consequences (chapter 5). As platelet contribution is fundamental in determining the outcome of percutaneous coronary revascularisation, in part III the question whether geometry and design of stents (chapter 6), and how different antiplatelet therapies (antiaggregants or GpIIbIIIa inhibitors) (chapter 7) can influence platelet activation during stenting will be considered. Finally (part IV), endothelium-dependent and independent vasomotion of grafted internal thoracic arteries long-term after surgery (chapter 8), and the effect of various risk factors (smoking in particular) on arterial graft vasomotion (chapter 9) are investigated. A comprehensive overview of our results with conclusive remarks and clinical implications complete the thesis. Summaries both in Dutch and in Italian are also provided.
Pathology of Coronary Artery Disease
Pathology of Coronary Artery Disease Seth J. Kligerman, MD Pathology of Coronary Artery Disease Seth Kligerman, MD Assistant Professor Medical Director of MRI University of Maryland Department of Radiology
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationChanges in Coronary Plaque Color and Morphology by Lipid-Lowering Therapy With Atorvastatin: Serial Evaluation by Coronary Angioscopy
Journal of the American College of Cardiology Vol. 42, No. 4, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00770-8
More informationBy Graham C. Wong, MD; and Christian Constance, MD. therapy in reducing long-term cardiovascular
Lipid-Lowering Therapy For Acute Coronary Syndromes There is a large amount of evidence that supports the early use of statins in the treatment of acute coronary syndromes. The anti-inflammatory, anti-thrombotic
More informationIntervention: How and to which extent is technology helping us?
Cardiological Society of India Congress 12th February 2016 Chennai, India Intervention: How and to which extent is technology helping us? SIMONE BISCAGLIA MD CARDIOVASCULAR INSTITUTE, FERRARA, ITALY Introduction
More informationInfluence of Planned Six-Month Follow-Up Angiography on Late Outcome After Percutaneous Coronary Intervention A Randomized Study
Journal of the American College of Cardiology Vol. 38, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01476-0 Influence
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationCOURAGE to Leave Diseased Arteries Alone
COURAGE to Leave Diseased Arteries Alone Spencer King MD MACC, FSCAI St. Joseph s s Heart and Vascular Institute Professor of Medicine Emeritus Emory Univ. Atlanta, USA Conflict: I am an Interventionalist
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More informationDiabetes and Occult Coronary Artery Disease
Diabetes and Occult Coronary Artery Disease Mun K. Hong, MD, FACC, FSCAI Director, Cardiac Catheterization Laboratory & Interventional Cardiology St. Luke s-roosevelt Hospital Center New York, New York
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationCoronary Plaque Sealing: The DEFER Study and more...
Coronary Plaque Sealing: The DEFER Study and more... How Waiting Can Be Beneficial in Stable Coronary Artery Disease Patients ESC, Stockholm, 2005 M. Romanens, 21.09.2005 at www.kardiolab.ch DEFER Study:
More informationNoninvasive Coronary Imaging: Plaque Imaging by MDCT
Coronary Physiology & Imaging Summit 2007 Noninvasive Coronary Imaging: Plaque Imaging by MDCT Byoung Wook Choi Department of Radiology Yonsei University, Seoul, Korea Stary, H. C. et al. Circulation
More informationBy 2000, more than percutaneous and
Review: Current Perspective Indications for Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention in Chronic Stable Angina Review of the Evidence and Methodological Considerations Charanjit
More informationEvolution In Interventional Cardiology. Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands
Evolution In Interventional Cardiology Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands 25 November 2010 Coronary Atherosclerosis Timeline in interventional cardiology Indications for
More informationNEW INTERVENTIONAL TECHNOLOGIES
by Lawrence M Prescott, PhD NEW INTERVENTIONAL TECHNOLOGIES EXPAND TREATMENT OPTIONS FOR CARDIOVASCULAR DISEASE Novel interventional techniques are proving to be of particular value in the treatment of
More informationVascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationAnatomy is Destiny, But Physiology is Here Today
Published on Journal of Invasive Cardiology (http://www.invasivecardiology.com) September, 2010 [1] Anatomy is Destiny, But Physiology is Here Today Thu, 9/9/10-10:54am 0 Comments Section: Commentary Issue
More informationStatins in the elderly: What evidence of their benefit in prevention?
Archives of Cardiovascular Disease (2010) 103, 61 65 SCIENTIFIC EDITORIAL Statins in the elderly: What evidence of their benefit in prevention? Les statines chez les personnes âgées : quelle preuve de
More informationComparison of Long-term Efficacy of Medical Treatment versus Percutaneous Transluminal Coronary Angioplasty (PTCA) in Single-vessel Disease
Comparison of Long-term Efficacy of Medical Treatment versus Percutaneous Transluminal Coronary Angioplasty (PTCA) in Single-vessel Disease Shinichiro NISHIYAMA, M.D., Takashi IWASE, M.D., Sugao ISHIWATA,
More informationCottrell Memorial Lecture. Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease?
Cottrell Memorial Lecture Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease? Stephen Nicholls MBBS PhD @SAHMRI_Heart Disclosures Research support: AstraZeneca,
More informationCoronary Artery Thermography
Coronary Artery Thermography The 10th Anniversary, Interventional Vascular Therapeutics Angioplasty Summit 2005 TCT Asia Pacific Christodoulos Stefanadis Professor of Cardiology Athens Medical School In
More informationUntil recently, atherosclerosis was
Heart 2000;83:247 252 CORONARY DISEASE Atherogenesis: current understanding of the causes of atheroma Peter L Weissberg School of Clinical Medicine, University of Cambridge, Cambridge, UK Correspondence
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationPathology of Cardiovascular Interventions. Body and Disease 2011
Pathology of Cardiovascular Interventions Body and Disease 2011 Coronary Artery Atherosclerosis Intervention Goals: Acute Coronary Syndromes: Treat plaque rupture and thrombosis Significant Disease: Prevent
More informationControversies in Cardiac Surgery
Controversies in Cardiac Surgery 3 years after SYNTAX : Percutaneous Coronary Intervention for Multivessel / Left main stem Coronary artery disease Pro ESC Congress 2010, 28 August 1 September Stockholm
More informationState of the Art. Advances in Cardiovascular Imaging. ESC Congres Stockholm September 1, 2010 Frank E. Rademakers, MD, PhD, FESC
State of the Art Advances in Cardiovascular Imaging ESC Congres Stockholm September 1, 2010 Frank E. Rademakers, MD, PhD, FESC Coronary Artery Disease Content Patho Physiology Imaging requirements Economical
More informationTitle for Paragraph Format Slide
Title for Paragraph Format Slide Presentation Title: Month Date, Year Atherosclerosis A Spectrum of Disease: February 12, 2015 Richard Cameron Padgett, MD Executive Medical Director, OHVI Pt RB Age 38
More informationEffects of Statins on Endothelial Function in Patients with Coronary Artery Disease
Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease Iana I. Simova, MD; Stefan V. Denchev, PhD; Simeon I. Dimitrov, PhD Clinic of Cardiology, University Hospital Alexandrovska,
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationSetting The setting was a hospital. The economic study was carried out in Australia.
Coronary artery bypass grafting (CABG) after initially successful percutaneous transluminal coronary angioplasty (PTCA): a review of 17 years experience Barakate M S, Hemli J M, Hughes C F, Bannon P G,
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More information대한심장학회춘계학술대회 Satellite Symposium
대한심장학회춘계학술대회 Satellite Symposium Coronary Plaque Regression and Compositional Changes by Lipid-Lowering Therapy: IVUS Substudy in Livalo (Pitavastatin) in Acute Myocardial Infarction Study (LAMIS) Livalo
More informationJames M. Kirshenbaum, MD, FACC
James M. Kirshenbaum, MD, FACC Associate Professor of Medicine Harvard Medical School Co-Director, Clinical Cardiology Director, Acute Interventional Cardiology Brigham and Women s Hospital Boston, MA
More informationAtherosclerotic disease regression with statins: studies using vascular markers
International Journal of Cardiology 96 (2004) 447 459 www.elsevier.com/locate/ijcard Atherosclerotic disease regression with statins: studies using vascular markers Diederick E. Grobbee*, Michiel L. Bots
More informationCoronary Artery Calcium Score
Coronary Artery Calcium Score August 19, 2014 by Axel F. Sigurdsson MD 174 Comments essential for living organisms. Calcium is a chemical element that is Most of the calcium within the human body is found
More informationSTATINS FOR PAD Long - term prognosis
STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest
More informationCardiovascular Disorders Lecture 3 Coronar Artery Diseases
Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in
More informationThe Case for Intravenous EDTA Chelation Therapy, August, 2006 update.
The Case for Intravenous EDTA Chelation Therapy, August, 2006 update. Positive Dr. Johanna Mendez (Columbia, S.A.) and Dr. Martin Dayton discussing contents of a chelation treatment in a clinical setting
More informationΣεμινάριο Ομάδων Εργασίας Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική
ΕΛΛΗΝΙΚΗΚΑΡΔΙΟΛΟΓΙΚΗΕΤΑΙΡΕΙΑ Σεμινάριο Ομάδων Εργασίας 2011 Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική GUIDELINES ON MYOCARDIAL
More informationInvited Review. Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases
Histol Histopathol (2000) 15: 557-571 Histology and Histopathology Cellular and Molecular Biology Invited Review Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular
More informationThe 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories
The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories Cardiac biomarkers in atherosclerosis Najma Asadi MD-APCP Ross and Colleagues in 1973: Response to Injury
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationCost effectiveness of statin therapy for the primary prevention of coronary heart disease in Ireland Nash A, Barry M, Walshe V
Cost effectiveness of statin therapy for the primary prevention of coronary heart disease in Ireland Nash A, Barry M, Walshe V Record Status This is a critical abstract of an economic evaluation that meets
More informationIschaemic heart disease. IInd Chair and Clinic of Cardiology
Ischaemic heart disease IInd Chair and Clinic of Cardiology Definition Syndrome due to chronic insufficient oxygen supply to myocardial cells Nomenclature: ischaemic heart disease (IHD), coronary artery
More informationΔημήτριος Αγγοσράς, FETCS
ΣΕΜΙΝΑΡΙΟ ΟΜΑΔΩΝ ΕΡΓΑΣΙΑΣ Δημήτριος Αγγοσράς, FETCS Επίκοσρος Καθηγηηής Καρδιοτειροσργικής Ιαηρική Πανεπιζηημίοσ Αθηνών Πανεπιζηημιακό Γενικό Νοζοκομείο Αηηικόν Randomized Controlled Trials (RCTs) Why
More informationZachary I. Hodes, M.D., Ph.D., F.A.C.C.
Zachary I. Hodes, M.D., Ph.D., F.A.C.C. Disclamer: I personally have no financial relationship with any company mentioned today. The Care Group, LLC does have a contract with Cardium to participate in
More informationAdded Value of Invasive Coronary Imaging for Plaque Rupture and Erosion
Assessment of Coronary Plaque Rupture and Erosion Added Value of Invasive Coronary Imaging for Plaque Rupture and Erosion Yukio Ozaki, MD, PhD, FACC, FESC Cardiology Dept., Fujita Health Univ. Toyoake,
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationΗ Πυρηνική Καρδιολογία Το 2017 ΟΜΑΔΑ ΕΡΓΑΣΙΑΣ ΑΠΕΙΚΟΝΙΣΤΙΚΩΝ ΤΕΧΝΙΚΩΝ
Η Πυρηνική Καρδιολογία Το 2017 ΟΜΑΔΑ ΕΡΓΑΣΙΑΣ ΑΠΕΙΚΟΝΙΣΤΙΚΩΝ ΤΕΧΝΙΚΩΝ huma human n Setting diagnosis of the early stages of chronic diseases (i.e cancer, neuropsychiatric, cardiovascular disorders), in
More informationEVect of cholesterol lowering treatment on positive exercise tests in patients with hypercholesterolaemia and normal coronary angiograms
Heart 1999;82:689 693 689 Heart Institute, São Paulo University, Av Dr Enéas de Carvalho Aguiar 44, 05403-000 São Paulo, Brazil A P Mansur C V Serrano J C Nicolau L A M César J A F Ramires Correspondence
More informationFFR Incorporating & Expanding it s use in Clinical Practice
FFR Incorporating & Expanding it s use in Clinical Practice Suleiman Kharabsheh, MD Consultant Invasive Cardiology Assistant professor, Alfaisal Univ. KFHI - KFSHRC Concept of FFR Maximum flow down a vessel
More informationactually rupture! Challenges to the vulnerable plaque concept
An Update on the Pathogenesis of the Acute Coronary Syndromes Peter Libby Brigham & Women s Hospital Harvard Medical School ADVANCES IN HEART DISEASE University of California San Francisco December 20,
More information2/17/2010. Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco
Modern Management of Patients with Stable Coronary Artery Disease Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco Scope of the Problem Prevalence of CAD: 17.6 million
More informationImaging Atheroma The quest for the Vulnerable Plaque
Imaging Atheroma The quest for the Vulnerable Plaque P.J. de Feijter 1. Department of Cardiology 2. Department of Radiology Coronary Heart Disease Remains the Leading Cause of Death in the U.S, Causing
More informationSeven-Year Outcome in the RITA-2 Trial: Coronary Angioplasty Versus Medical Therapy
Journal of the American College of Cardiology Vol. 42, No. 7, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00951-3
More informationHow to approach non-infarct related artery disease in patients with STEMI in a limited resource setting
How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,
More informationIschemic heart disease
Ischemic heart disease Introduction In > 90% of cases: the cause is: reduced coronary blood flow secondary to: obstructive atherosclerotic vascular disease so most of the time it is called: coronary artery
More informationPCI in Patients with Transplant Coronary Artery Disease. Michael S. Lee, MD, FACC, FSCAI Assistant Professor UCLA School of Medicine
PCI in Patients with Transplant Coronary Artery Disease Michael S. Lee, MD, FACC, FSCAI Assistant Professor UCLA School of Medicine Faculty Disclosure Honararia for Boston Scientific, BMS, Daiichi Sankyo,
More informationΚλινική Χρήση IVUS και OCT PERIKLIS A. DAVLOUROS ASSOCIATE PROFESSOR OF CARDIOLOGY INVASIVE CARDIOLOGY & CONGENITAL HEART DISEASE
Κλινική Χρήση IVUS και OCT PERIKLIS A. DAVLOUROS ASSOCIATE PROFESSOR OF CARDIOLOGY INVASIVE CARDIOLOGY & CONGENITAL HEART DISEASE Conflict of interest None to declare While IVUS is the most used intravascular
More informationLAMIS (Livalo in AMI Study)
JCR 2018. 12. 8 LAMIS (Livalo in AMI Study) Young Joon Hong Division of Cardiology, Chonnam National University Hospital Gwangju, Korea Trend of hypercholesterolemia in Korea < Prevalence of hypercholesterolemia
More informationAtherosclerosis Regression An Overview of Recent Findings & Issues
Atherosclerosis Regression An Overview of Recent Findings & Issues 13th Angioplasty Summit 2008 Cheol Whan Lee, MD University of Ulsan, Asan Medical Center, Seoul, Korea CardioVascular Research Foundation
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationPharmacologic Therapy of Coronary Disease
Pharmacologic Therapy of Coronary Disease M. MOHSEN IBRAHIM, MD Prof. of Cardiology- Cairo University President of the Egyptian Hypertension Society Introduction Coronary artery disease (CAD) is possibly
More informationJournal of the American College of Cardiology Vol. 38, No. 5, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 38, No. 5, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01571-6 Survival
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/43967 holds various files of this Leiden University dissertation Author: Graaf, Michiel A. de Title: Computed tomography coronary angiography : from quantification
More informationMaria Angela S. Cruz-Anacleto, MD
Maria Angela S. Cruz-Anacleto, MD 57/Female Menopausal Non-HTN, non-dm Hypothyroid (s/p RAI 1997) Levothyroxine 100 ug OD 5 Months PTA Chest discomfort Stress Echocardiography 5 Months PTA Chest discomfort
More informationCLINICAL INVESTIGATION OF ANTI-ANGINAL MEDICINAL PRODUCTS IN STABLE ANGINA PECTORIS
CLINICAL INVESTIGATION OF ANTI-ANGINAL MEDICINAL PRODUCTS IN STABLE ANGINA PECTORIS Guideline Title Clinical Investigation of Anti-Anginal Medicinal Products in Stable Angina Pectoris Legislative basis
More informationChest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham
Chest pain and troponins on the acute take J N Townend Queen Elizabeth Hospital Birmingham 3 rd Universal Definition of Myocardial Infarction Type 1: Spontaneous MI related to atherosclerotic plaque rupture
More informationImaging the Vulnerable Plaque. David A. Dowe, MD Atlantic Medical Imaging
Imaging the Vulnerable Plaque David A. Dowe, MD Atlantic Medical Imaging Why is this so important? The Acute Situation Coronary disease-important Diagnosis of cardiovascular disease cost $148 billion in
More informationCoronary plaque erosion: a clinical case. Dr. Giampaolo Niccoli, MD, PhD, FESC Institute of Cardiology Catholic University, Rome, Italy
Coronary plaque erosion: a clinical case, MD, PhD, FESC Institute of Cardiology Catholic University, Rome, Italy Coronary plaque erosion: a clinical case B.M. Age: 59 years Sex: female. Cardiological risk
More informationQuinn Capers, IV, MD
Heart Attacks Mended Hearts Presentation, January, 2017 Quinn Capers, IV, MD Associate Professor of Medicine (Cardiovascular Medicine) Director, Transradial Coronary Interventions Division of Cardiovascular
More informationFFR-CT Not Ready for Primetime
FFR-CT Not Ready for Primetime Leslee J. Shaw, PhD, MASNC, FACC, FAHA, FSCCT R. Bruce Logue Professor of Medicine Co-Director, Emory Clinical CV Research Institute Emory University School of Medicine Atlanta,
More informationType of intervention Diagnosis. Economic study type Cost-effectiveness analysis.
The utility and potential cost-effectiveness of stress myocardial perfusion thallium SPECT imaging in hospitalized patients with chest pain and normal or non-diagnostic electrocardiogram Ben-Gal T, Zafrir
More informationPearls & Pitfalls in nuclear cardiology
Pearls & Pitfalls in nuclear cardiology Maythinee Chantadisai, MD., NM physician Division of Nuclear Medicine, Department of radiology, KCMH Principle of myocardial perfusion imaging (MPI) Radiotracer
More informationImportance of the third arterial graft in multiple arterial grafting strategies
Research Highlight Importance of the third arterial graft in multiple arterial grafting strategies David Glineur Department of Cardiovascular Surgery, Cliniques St Luc, Bouge and the Department of Cardiovascular
More informationVulnerable Plaque Pathophysiology, Detection, and Intervention. VP: A Local Problem or Systemic Disease. Erling Falk, Denmark
Vulnerable Plaque Pathophysiology, Detection, and Intervention VP: A Local Problem or Systemic Disease Erling Falk, Denmark Vulnerable Plaque Pathophysiology, Detection, and Intervention VP: A Local Problem
More informationHeart Disease in Women: Is it Really Different?
Heart Disease in Women: Is it Really Different? Jennifer Jarbeau, MD Southcoast Physicians Group Cardiovascular Associates of RI Disclosures I have no financial interests to disclose I wish I did! Are
More informationProgression of coronary atherosclerosis may lead to angina
Regression of Coronary Atherosclerosis by Simvastatin A Serial Intravascular Ultrasound Study Lisette Okkels Jensen, MD, PhD; Per Thayssen, MD, DMSci; Knud Erik Pedersen, MD, DMSci; Steen Stender, MD,
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationArteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More informationIntravascular Ultrasound
May 2008 Beth Israel Deaconess Medical Center Harvard Medical School Intravascular Ultrasound Matthew Altman, HMS III Gillian Lieberman, MD BIDMC Department of Radiology Presentation Overview 1. Patient
More informationStable Ischemic Heart Disease. Ivan Anderson, MD RIHVH Cardiology
Stable Ischemic Heart Disease Ivan Anderson, MD RIHVH Cardiology Outline Review of the vascular biology of atherosclerosis Why not just cath everyone with angina? Medical management of ischemic cardiomyopathy
More informationEvaluating Clinical Risk and Guiding management with SPECT Imaging
Evaluating Clinical Risk and Guiding management with SPECT Imaging Raffaele Giubbini Chair and Nuclear Medicine Unit University & Spedali Civili Brescia- Italy U.S. Congressional Budget Office. Technological
More informationImaging Overview for Vulnerable Plaque: Data from IVUS Trial and An Introduction to VH-IVUS Imgaging
Imaging Overview for Vulnerable Plaque: Data from IVUS Trial and An Introduction to VH-IVUS Imgaging Gary S. Mintz,, MD Cardiovascular Research Foundation New York, NY Today, in reality, almost everything
More informationOptimal testing for coronary artery disease in symptomatic and asymptomatic patients
Optimal testing for coronary artery disease in symptomatic and asymptomatic patients Alexandre C Ferreira, MD Clinical Chief of Cardiology Jackson Health System Director, Interventional Cardiology Training
More informationSTABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:
More informationClinical Investigation and Reports
Clinical Investigation and Reports Prognostic Impact of Coronary Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart Disease Volker Schächinger, MD; Martina B. Britten, MD; Andreas M.
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationImaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD
Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD Hein J. Verberne Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands International Conference
More informationRelationship Between Atheroma Regression and Change in Lumen Size After Infusion of Apolipoprotein A-I Milano
Journal of the American College of Cardiology Vol. 47, No. 5, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.11.040
More informationCT Imaging of Atherosclerotic Plaque. William Stanford MD Professor-Emeritus Radiology University of Iowa College of Medicine Iowa City, IA
CT Imaging of Atherosclerotic Plaque William Stanford MD Professor-Emeritus Radiology University of Iowa College of Medicine Iowa City, IA PREVALENCE OF CARDIOVASCULAR DISEASE In 2006 there were 80 million
More informationJMSCR Vol 07 Issue 01 Page January 2018
www.jmscr.igmpublication.org Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i1.109 Short Term Outcome in a Severe Coronary Artery Disease with
More informationSmooth muscle pharmacology & interventional cardiology
LAST LECTURE Smooth muscle & interventional cardiology By: Pascal Bernatchez Classic Vascular -chronic -systemic Local Vascular -acute -targeted High blood pressure Blood pressure control Atherosclerosis
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationPatient referral for elective coronary angiography: challenging the current strategy
Patient referral for elective coronary angiography: challenging the current strategy M. Santos, A. Ferreira, A. P. Sousa, J. Brito, R. Calé, L. Raposo, P. Gonçalves, R. Teles, M. Almeida, M. Mendes Cardiology
More informationArterial Wall Remodeling in Response to Atheroma Regression with Very Intensive Lipid Lowering
Arterial Wall Remodeling in Response to Atheroma Regression with Very Intensive Lipid Lowering Matthew I. Worthley MB BS, PhD, FRACP, FCSANZ, FACC Senior Lecturer/ Interventional Cardiologist University
More information